Plasma levels of voriconazole administered via a nasogastric tube to critically ill patients

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 24, Issue 5, 2005, Pages 358-360

  Mohammedi, I ^a   Piens, M A ^b   Padoin, C ^c   Robert, D ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b UNIVERSITÉ LYON 1   (France)

^c AVICENNE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

VORICONAZOLE;

ADULT; AGED; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; BLOOD SAMPLING; CANDIDA KEFYR; CANDIDIASIS; CLINICAL ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG METABOLISM; DRUG SENSITIVITY; ENTERIC FEEDING; FEMALE; HUMAN; INTENSIVE CARE UNIT; MALE; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NASOGASTRIC TUBE; PRIORITY JOURNAL; SCORING SYSTEM; STEADY STATE; TABLET;

AGED; ANTIFUNGAL AGENTS; CRITICAL ILLNESS; FEMALE; HUMANS; INTUBATION, GASTROINTESTINAL; MALE; MIDDLE AGED; MYCOSES; PROSPECTIVE STUDIES; PYRIMIDINES; TRIAZOLES;

EID: 21244433832     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-005-1325-7     Document Type: Article

References (11)

1. Martin GS, Mannino DM, Eaton S, Moss M (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348:1546-1554
2. Pearson MM, Rogers PD, Cleary JD, Chapman SW (2003) Voriconazole: a new triazole antifungal agent. Ann Pharmacother 37:420-432
3. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D (2002) Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 46:2546-2553
4. Martinez V, Le Guillou JL, Lamer C, Le Jouan M, Tod M, Dromer F (2003) Serum voriconazole levels following administration via percutaneous jejunostomy tube. Antimicrob Agents Chemother 47:3375
5. Le Gall JR, Lemeshow S, Saulnier F (1993) A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 270:2957-2963
6. Pennick GJ, Clark M, Sutton DA, Rinaldi MG (2003) Development and validation of a high-performance liquid chromatography assay for voriconazole. Antimicrob Agents Chemother 47:2348-2350
7. Sheehan DJ, Hitchcock CA, Sibley CM (1999) Current and emerging azole antifungal agents. Clin Microbiol Rev 12:40-79
8. Purkins L, Wood N, Greenhalgh K, Allen MJ, Oliver SD (2003) Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol 56(Supp 11):10-16
9. Rex JH, Pfaller MA (2002) Has antifungal susceptibility testing come of age? Clin Infect Dis 35:982-999
10. Staudinger T, Stoiser B, Mullner M, Locker GJ, Laczika K, Knapp S, Burgmann H, Wilfing A, Kofler J, Thalhammer F, Frass M (2000) Outcome and prognostic factors in critically ill cancer patients admitted to the intensive care unit. Crit Care Med 28:1322-1328
11. Benoit DD, Vandewoude KH, Decruyenaere JM, Hoste EA, Colardyn FA (2003) Outcome and early prognostic indicators in patients with a hematologic malignancy admitted to the intensive care unit for a life-threatening complication. Crit Care Med 31:104-112